ExLibris header image
SFX Logo
Title: New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
Source:

Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences [1570-0232] De Francia, Silvia yr:2009


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Comparsi Wagner, Simone C. "Characterization of imatinib mesylate formulations distributed in South American countries: Determination of genotoxic impurities by UHPLC-MS/MS and dissolution profile." Biomedical Chromatography 32.7 (2018). Link to Full Text for this item Link to SFX for this item
2. "In a large Phase III clinical trial, Tasigna (nilotinib) 200 mg capsules demonstrated greater efficacy over Gleevec (imatinib mesylate) tablets in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukem." Applied clinical trials 19.5 (2010). Link to SFX for this item
3. J E Cortes; M J Egorin; F Guilhot; M Molimard; F-X Mahon;, F-X X. "Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia." Leukemia 23.9 (2009): 1537-1544. Link to Full Text for this item Link to SFX for this item
4. "The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19." Trials. 23.1: 158-158. Link to SFX for this item
5. "Novartis long-term Phase III data show Ph CML patients on Tasigna[R] achieved significantly deeper molecular response versus Gleevec[R]." Clinical trials week (2012): 203-. Link to SFX for this item
6. Barceló, D. "Multianalyte determination of 24 cytostatics and metabolites by liquid chromatography-electrospray-tandem mass spectrometry and study of their stability and optimum storage conditions in aqueous solution." Talanta 116.C (2013): 290-9. Link to SFX for this item
7. Arellano, C. "Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS/MS assay and ultrafiltration method." Journal of chromatography. B 907 (2012): 94-100. Link to SFX for this item
8. Albrecht, I. "Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study." Blood 113.22 (2009): 5401-5411. Link to SFX for this item
9. Lacey, J. "Barriers to adherence with glaucoma medications: a qualitative research study." Eye 23.4 (2009): 924-932. Link to Full Text for this item Link to SFX for this item
10. Peng, B. "Clinical pharmacokinetics of imatinib." Clinical pharmacokinetics 44.9 (2005): 879-94. Link to SFX for this item
11. RAMAKRISHNA, K. "Development and validation of GC-MS method for the determination of methyl methanesulfonate and ethyl methanesulfonate in imatinib mesylate." Journal of Pharmaceutical and Biomedical Analysis 46.4 (2008): 780-783. Link to SFX for this item
12. van Erp, Nielka P. "Clinical pharmacokinetics of tyrosine kinase inhibitors." Cancer Treatment Reviews 35.8 (2009): 692-706. Link to SFX for this item
13. Marin, D. "Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib." Journal of clinical oncology 28.14 (2010): 2381-2388. Link to SFX for this item
14. Young, A M M. "Can pharmacokinetic monitoring improve clinical use of fluorouracil?" Clinical pharmacokinetics 36.6 (1999): 391-8. Link to SFX for this item
15. Abbott, R. "Are community pharmacists equipped to ensure the safe use of oral anticancer therapy in the community setting? Results of a cross-country survey of community pharmacists in Canada." Journal of oncology pharmacy practice 20.1 (2013): 29-39. Link to Full Text for this item Link to SFX for this item
16. Cortes, J. "Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia." PharmacoEconomics 25.6 (2007): 481-96. Link to SFX for this item
17. Leong, Gwyneth L. "Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma." Ophthalmology 117.5 (2010): 903-908. Link to SFX for this item
18. Mortier, Kjell A A. "Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry." Journal of chromatography 1108.2 (2006): 195-201. Link to SFX for this item
19. Goodin, S. "Oral chemotherapeutic agents: Understanding mechanisms of action and drug interactions." American journal of health-system pharmacy 64.9 Suppl 5 (2007): -24. Link to SFX for this item
20. Zhang, C. "Determination of sulfonate ester genotoxic impurities in imatinib mesylate by gas chromatography with mass spectrometry." Journal of Separation Science 39.18 (2016): 3558-3563. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.